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Missense mutations in the cystathionine b-synthase (CBS) gene are the most common cause of clinical
homocystinuria in humans. The p.S466L mutation was identified in a homocystinuric patient, but enzymatic
studies with recombinant protein show this mutant to be highly active. To understand how this mutation causes
disease in vivo, we have created mice lacking endogenous mouse CBS and expressing either wild-type (Tg-
hCBS) or p.S466L (Tg-S466L) human CBS under control of zinc inducible metallothionein promoter. In the
presence of zinc, we found that the mean serum total homocysteine (tHcy) of Tg-S466L mice was 142755lM
compared to 16713lM for hCBS mice. Tg-S466L mice also had significantly higher levels of total free
homocysteine and S-adenosylhomocysteine in liver and kidney. Only 48% of Tg-S466L mice had detectable
CBS protein in the liver, whereas all the Tg-hCBS animals had detectable protein. Surprisingly, CBS mRNAwas
significantly elevated in Tg-S466L animals compared to Tg-hCBS, implying that the reduction in p.S466L
protein was occurring due to posttranscriptional mechanisms. In Tg-S466L animals with detectable liver CBS,
the enzyme formed tetramers and was active, but lacked inducibility by S-adenosylmethionine (AdoMet).
However, even in Tg-S466L animals that had in vitro liver CBS activity equivalent to Tg-hCBS animals there
was significant elevation of serum tHcy. Our results show that p.S466L causes homocystinuria by affecting both
the steady state level of CBS protein and by reducing the efficiency of the enzyme in vivo. Hum Mutat
29(8),1048–1054, 2008. r r 2008 Wiley-Liss, Inc.
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INTRODUCTION
Cystathionine b-synthase (CBS; EC 4.2.1.22; MIM] 236200) is
a key enzyme in the transsulfuration pathway that regulates
homocysteine homeostasis. Mutations in the CBS gene cause
clinical CBS deficiency (homocystinuria), a metabolic disorder
characterized by extreme elevations in plasma total homocysteine
(tHcy). The natural history of untreated CBS deficiency includes
the development of venous thrombosis, arteriosclerosis, ectopia
lentis, developmental delay, and osteoporosis [Mudd et al., 2001].
The enzyme is a cytosolic homotetramer consisting of four 63-kDa
subunits [Kraus et al., 1993, 1986]. CBS has three functional
domains: a heme binding domain, a catalytic core domain, and a
C-terminal regulatory domain [Jhee and Kruger, 2005]. The
C-terminal regulatory domain binds S-adenosylmethionine (Ado-
Met), an allosteric effector that results in a three-fold increase in
Vmax for the enzyme [Taoka et al., 1998]. Most disease-causing
mutations in CBS are of the missense variety [Kraus et al., 1999].
The p.S466L (c.1397C4T) mutation of CBS was originally
described in a compound heterozygote along with a p.I278T
(c.833T4C) mutation. This patient had thrombosis and elevated
tHcy (167mM) but lacked other clinical signs associated with CBS
deficiency [Gaustadnes et al., 2000]. Surprisingly, expression of
recombinant p.S466L in either bacterial or mammalian cellular
expression systems demonstrate that p.S466L is catalytically
active, although it is no longer stimulated by AdoMet [Janosik
et al., 2001; Maclean et al., 2002]. Since it is known that the
p.I278Talteration is not dominant, the question arises as to why
the patient had clinical disease. To address this issue we have
created mouse models that lack endogenous mouse CBS and
express either wild-type human CBS or p.S466L under the control
of zinc inducible metallothionein promoter. Our results show that
the p.S466L mutation results in reduced levels of CBS protein
resulting in severe hyperhomocysteinemia in vivo.
MATERIALSANDMETHODS
DNA and Constructs
All nucleotide numbering is based on the GenBank RefSeq
NM_000071.1. The DNA mutation numbering system is based on
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translation initiation codon in the reference sequence. The
initiator codon is codon 1 in the protein sequence. Site-directed
mutagenesis was used to introduce a c.1397C4T (p.S466L)
change into pLW2, which contains a hemagglutinin epitope–-
tagged version of the human CBS cDNA [Wang et al., 2004] using
the Quick Change XL site-directed mutagenesis kit from
Stratagene (La Jolla, CA). The entire open reading frame of the
resulting clone, pLW2:466, was sequenced to verify no additional
changes occurred. Plasmid pLW2:466 was subsequently digested
with MfeI and cloned into MT-LCR expression vector 2999
(obtained from Richard Palmiter, University of Washington,
Seattle) [Palmiter et al., 1993]. The resulting plasmid was
designated pLW3:466.
Yeast St udies
The c.1397C4T (p.S466L) mutation was introduced into yeast
strain WY35 (MATa ura3-52 his3 trp1 cys4::LEU2) using gap
repair as previously described [Shan et al., 2001].
Mouse Generation
Transgenic mice containing pLW3:466 were created as
previously described [Wang et al., 2004]. In brief, DNA was
digested with SalI, purified and microinjected into the pronuclei of
day 0.5 C57B6/C3H F2 embryos. Injected embryos were then
transferred to pseudopregnant mice. Tails from the resulting pups
were then screened for the presence of the transgene by PCR as
described [Wang et al., 2004]. DNA-positive animals were then
bred to C57B6 animals and the offspring was then tested for
germline transmission. Of the five pLW3:466 founders, three had
germline transmission. Offspring of all three lines were given
25mmol/L ZnSO4 for 10 days and examined for transgene
expression by Western blot. Offspring from line EB86 gave the
highest expression, so this line was chosen for further study.
To create mice that only had p.S466L CBS, transgene-positive
offspring were bred to C57B6 Cbs
 heterozygous animals originally
obtained from Jackson Laboratories (Bar Harbor, ME) to obtain
Tg
1 Cbs
/1 animals [Watanabe et al., 1995]. These animals were
then backcrossed again to C57B6 Cbs
 heterozygous animals to
obtain Tg
1 Cbs
/ animals. To generate large numbers of Tg
1
Cbs
/ animals, male Tg
1 Cbs
/ mice were bred with female
Tg
1 Cbs
/1. All crosses were done in the presence of 25mmol/L
ZnSO4 water to induce transgene expression. Tg-S466L Cbs
/
offspring were generated at expected Mendelian frequencies and
had no obvious phenotypes compared to Tg-hCBS Cbs
/ animals.
Genotyping of offspring was generally done at the time of
weaning as previously described [Wang et al., 2004]. Animals were
fed standard rodent chow (Teklad 2018SX, Harlen Teklad,
Madison, WI) containing 0.43% methionine by weight.
Metabolite Measurements
Serum tHcy and methionine were measured using a Biochrom
30 amino acid analyzer (Cambridge, UK) as previously described
[Wang et al., 2004]. tHcy refers to the sum total of all forms of
homocysteine, including protein-bound, free-reduced, and free-
oxidized. For tissue metabolites, tissues were frozen immediately
after excision, ground, and deproteinized in perchloric acid to
prevent possible enzymatic conversions of the metabolites. For
AdoMet/S-adenosylhomocysteine (AdoHcy) analysis, we used a
short (502.1mm) graphite column (Hypercarb; Thermo
Scientific, Waltham, MA) for retention and separation of AdoMet
and AdoHcy from early eluting salts and matrix compounds. The
AdoMet/AdoHcy were detected and quantified using an LCQ
Advantage Max ion-trap mass spectrometer (Thermo Scientific)
operated in positive-ion (ESI1) mode. Multiple-reaction monitor-
ing conditions were optimized for AdoMet (m/z 399-250),
AdoHcy (m/z 385-250), and stable-isotope internal standards
2H3-AdoMet (m/z 402-250) and
13C5-AdoHcy (m/z 390-255).
The calibration curves were linear (r
240.99) in the range
0.5–100mmol/L, the intra- and interassay coefficients of variance
(CVs) were o10%.
For tissue aminothiol analysis, the supernatant was reduced with
Tris (2-carboxyethyl) phosphine (TCEP) and derivatized with
ammonium7-fluorobenzo-2-oxa-1, 3-diazole-4-sulfonate (SBD-F)
as described [Krijt et al., 2001]. A 10-mL aliquot of derivatized
sample was injected onto an reverse phase (RP) C18 column
(Prontosil C18-AQ, 2504.0mm, 3.0mm; Bischoff Chromato-
graphy, Leonberg, Germany) and aminothiols were eluted with
gradient of 50mM KH2PO4 (pH 1.9) in water to 50mM KH2PO4
(pH 1.9) in 30% acetonitrile. The fluorescence intensities were
measured with excitation at 385nm and emission at 515nm.
Because reduction occurred after deproteinization, this procedure
determines total free homocysteine, not tHcy.
Western Blotting and CBSEnzymeActivity
Liver and yeast homogenates were prepared as previously
described [Shan et al., 2001; Wang et al., 2005]. For Western
blotting, 30mg of total protein extract was electrophoresed on a
7% NuPAGE Tris-Acetate gel (Invitrogen, Carlsbad, CA) under
denaturing conditions followed by transfer on to a polyvinylidene
fluoride (PVDF) membrane (Bio Rad, Hercules, CA). For native
Western blotting, samples were run at 41C under nondenatured
conditions. CBS was detected using a polyclonal anti-human
primary antibody (1:10,000) and secondary anti-rabbit antibody
(1:30,000) conjugated with horseradish peroxidase (Amersham
Biosciences, Little Chalfont Buckinghamshire, UK). Signal was
visualized by SuperSignal West Pico Chemiluminescent kit
(Pierce, Rockford, IL) and signal was calculated using an Alpha
Innotech image analyzer (San Leandro, CA).
CBS activity was analyzed in the presence and absence of
AdoMet (250mM) as previously described [Wang et al., 2004]. One
unit of activity is defined as micromoles (mmol) of cystathionine
formed per milligram of protein per hr. For normalization studies the
amount of CBS was determined by Western analysis and the activity
in the p.S466L was multiplied by the densitometry ratio between
wild-type and p.S466L. For kinetic studies, a standard assay system
was used, keeping one substrate at saturating conditions and varying
the other from 0 to 40mM. Data was analyzed using GraphPad
Prism 4.0 software (San Diego, CA).
Quantitative Real-Time PCR
RNA was extracted from livers using TRIzol plus RNA
purification kit (Invitrogen). A total of 100ng of RNA was used
for Taq Man Gene expression analysis using two probes, one for
human CBS (Hs00163925_m1; Applied Biosystems, Foster City,
CA) and one for mouse b-actin (Mm00607939_s1; Applied
Biosystems). Quantification of signal was achieved using an
Applied Biosystems 7900HT version 2.2.2 sequence detection
system. Each sample was assayed in triplicate for both probes.
Relative signal strength was calculated using the DDCt method.
Statistics
All values cited in text and figures are arithmetic mean7
standard deviation (SD). t-Tests are all two-sided with Po0.05
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of regression lines was performed using GraphPad Prism 4.0.
RESULTS
p.S466L Expressed in S. cerevisiae Is Constitutively
Active
To determine the functional consequences of p.S466L, we
expressed human p.S466L in a yeast strain in which the
endogenous yeast CBS gene (CYS4) is deleted. As a result of
this mutation this strain cannot synthesize cysteine and exhibits a
cysteine auxotrophy. We found that expression of p.S466L allowed
growth on cysteine-free media, indicating that the p.S466L
enzyme is active (data not shown). To confirm this observation,
we prepared homogenates from yeast expressing either wild-type or
p.S466L and measured the amount of CBS present by Western
blot and the amount of CBS activity in the absence and presence
of AdoMet (Supplementary Fig. S1; available online at http://
www.interscience.wiley.com/jpages/1059-7794/suppmat). We found
that the amount of p.S466L protein was essentially identical to the
wild-type, and that its activity in the presence of AdoMet was only
slightly less than the wild-type. However, in the absence of AdoMet
the p.S466L enzyme was considerably more active than the wild-
type enzyme. Our data in yeast confirms previous observations that
recombinant p.S466L is stable and constitutively active.
Tg-S466L Mice Have Hyperhomocysteinemia
To determine the effect of p.S466L mutation on serum tHcy, we
created two genetically engineered mouse strains. These mice lack
endogenous mouse CBS and contain a transgene that expresses
either the wild-type human CBS protein (Tg-hCBS; see Wang
et al. [2004]) or the p.S466L protein (Tg-S466L, see Materials and
Methods) from a mouse metallothionein promoter. This promoter
can be activated in the liver and kidney by the addition of zinc to
the drinking water. Adult mice were kept on zinc water for 10 days
and then analyzed for their tHcy. The Tg-hCBS mice (n513) had
an average tHcy of 16713mM. In contrast, the Tg-S466L mice
(n531) had an average tHcy of 142755mM (hCBS vs. p.S466L;
Po0.0001; Mann-Whitney U-test) (Fig. 1A). Interestingly, these
animals exhibited wide variation in their tHcy, ranging from 26 to
285mM. Since human patients with hyperhomocysteinemia tend
to have hypermethionemia as well, we also measured serum
methionine levels [Mudd et al., 2001]. We did not observe a
statistically significant difference in serum methionine (Fig. 1B).
These results indicate that expression of p.S466L in mice causes
hyperhomocysteinemia with an absence of hypermethionemia.
We also measured the total free concentration of several
homocysteine-related metabolites in the liver, kidney, and brain of
Tg-hCBS and Tg-S466L mice. These metabolites included
cysteine, homocysteine, glutathione, cysteinyl-glycine, gamma-
glutamylcysteine, AdoMet, and AdoHcy. In the liver and kidney,
Tg-S466L mice had large elevations of both total free homo-
cysteine and AdoHcy (Fig. 2) as would be expected in CBS
deficiency. We did not observe any significant differences in any of
the other metabolites examined.
Variable Expression of p.S466L Protein
Although most of the Tg-S466L mice exhibited the severe
hyperhomocysteinemia (of more than 100mM), the high degree of
variability in their tHcy led us to examine the steady state levels of
p.S466L protein in mouse liver. Western blot analysis indicated that
there was large variation in the steady state levels of p.S466L protein
(Fig. 3A). Of the 29 p.S466L mice examined for CBS protein levels,
15 (52%) showed no detectable CBS protein, while the rest generally
had significantly less CBS than observed in control Tg-hCBS mice
(Fig. 3B). Animals with detectable CBS activity had slightly lower
mean tHcy compared to nondetectable animals, but the difference
was not statistically significant (128 vs. 137mM; P50.59). However,
it should be noted that 5 of the 6 animals with tHcy under 100mM
had detectable CBS levels (data not shown).
Elevated p.S466L mRNA inTg-S466L Mice
To understand the reason for variability and low-level expression
of p.S466L CBS, we measured steady state levels of human CBS
mRNA in the livers of Tg-hCBS and Tg-S466L mice. We found
that all of the p.S466L animals had significantly more CBS mRNA
compared to the Tg-hCBS animals (Supplementary Fig. S2). The
animals lacking CBS expression had on average 5.5-fold more CBS
mRNA, while the animals with detectable expression had on
average 10.2-fold more CBS mRNA. These findings show that
there is no problem with induction of the transgene by zinc in Tg-
S466L mice and implies that the effect of p.S466L mutation is to
reduce either protein production or stability.
Tg-S466L Is EnzymaticallyActive, FormsTetramers,
and Lacks AdoMet Inducibility
To further characterize the behavior of p.S466L CBS, we
measured CBS enzyme activity and tetramer formation in the liver
FIGURE 1. Serum tHcy and methionine inTg-S466L andTg-hCBS mice. Mice lacking mouse CBS containing either the p.S466L or
wild-type human CBS transgene were induced with zinc water for 10 days. Serum was then collected and analyzed for tHcy and
methionine. A: Distributionof tHcy measurements. Dots indicateindividual animals. Lines indicateaverage andstandarddeviation.
Thedi¡erence betweenthedistributions is highly signi¢cant (Po0.0001). B: Distributionofserum methionineconcentrations.
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CBS levels. First, we assessed CBS activity in the presence and
absence of allosteric activator AdoMet (Fig. 4A). We found that
CBS activity in Tg-hCBS liver homogenates (n53) was
0.14370.05mmol/mg/hr in the absence of AdoMet and increased
to 0.6370.29mmol/mg/hr, (4-fold; Po0.05; t-test) in the
presence of 250mM of AdoMet. In contrast, we found that
Tg-S466L liver homogenates (n56) with detectable CBS protein
expression had an insignificant change in CBS activity, from
0.3070.14mmol/mg/hr in the absence of AdoMet to
0.3370.15mmol/mg/hr in the presence of AdoMet. When the
enzyme activity of the Tg-S466L mice was normalized for CBS
protein levels, the specific activity of p.S466L was found to be
almost equivalent (0.670.26mmol/mg/hr) to wild-type CBS in the
FIGURE 2. Total free homocysteine andAdoHcy levels in tissues.Total free homocysteine and AdoHcy were measured in liver, kidney,
and brain fromTg-hCBS andTg-S466L animals as described in Materials and Methods. A:Tissue homocysteine content. Mean and
standarddeviation areshown. B:TissueAdoHcycontent. Po0.005; Po0.05.
FIGURE 3. CBS protein levels in the liver. Mice carrying the indicated transgene were induced with zinc water for 10 days and liver
extracts were assessed for CBS by Western blot. A: Representative Western blots showing the variable expression of CBS inTg-
S466L mice and in comparison withTg-hCBS mice. Actin loading control is shown below. B: Bar graph summarizingWestern data
for all 29 Tg-S466 mice assessedfor liverCBS protein.
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and E. coli studies indicating that p.S466L results in a
constitutively active CBS protein [Janosik et al., 2001; Maclean
et al., 2002].
We also examined the effect of the p.S466L mutation on
tetramer formation by utilizing native gels followed by Western
blotting (Fig. 4B). Again, we focused on Tg-S466L animals that
had detectable liver CBS protein. Our results show that the
p.S466L mutation does not cause a significant defect in tetramer
formation of the protein, although there may be a slight reduction
in the amount of higher-order octamer observed. When the
enzyme activity of the expressing Tg-S466L mice was normalized
for CBS tetramer levels, specific activity of p.S466L was again
found to be almost equivalent (0.5370.23mmol/mg/hr) to wild-
type hCBS in the presence of AdoMet (data not shown). This data
indicate that the p.S466L protein that is present in mouse liver is
enzymatically active, forms tetramers, but lacks AdoMet induci-
bility.
Relationship Between Liver CBS Protein, Activity, and
tHcy
We examined the relationship between the amount of CBS
tetramer present in liver homogenates from Tg-S466L and Tg-
hCBS animals and CBS activity. We found that there was a strong
linear relationship between the level of tetramer and CBS activity
for both Tg-hCBS and Tg-S466L animals (R
250.96; Fig. 5A).
Both the wild-type and the p.S466L animals appear to lie along the
same line. From these findings we conclude that the amount of
tetramer formed is a good predictor of CBS activity.
We also examined the relationship between liver CBS activity
and serum tHcy from mice with detectable liver CBS. We found
that there was a linear relationship for both Tg-hCBS and Tg-
S466L mice, but that the slope of the regression line differed
dramatically between the two groups (Po0.0003; Fig. 5B). For the
Tg-hCBS animals each one-unit decrease in liver CBS activity was
associated with a 14-mM increase in tHcy, while for Tg-S466L a
one-unit decrease in activity was associated with a 188-mM
increase. Furthermore, there were five p.S466L animals with
unnormalized liver CBS enzyme activity higher than the lowest of
the Tg-hCBS animals, but they still had substantially higher serum
tHcy. These findings suggest that in vivo p.S466L CBS is less
effective than wild-type CBS at lowering tHcy levels.
FIGURE 4. Examination of p.S466L and wild-type CBS enzyme activity and multimers formation. A: Enzyme activity and AdoMet
response of wild-type and p.S466L CBS.The ¢rst set of columns shows CBS activity in liver extracts derived fromTg-hCBS mice in
theabsenceandpresenceofAdoMet (n53).ThesecondsetofcolumnsshowsthesameforTg-S466Lmice (n56).Thethirdsetshows
therelativeTg-S466L activity whenadjustedfor totalp.S466LproteinasjudgedbyWesternblot analysis. B:Comparisonof theCBS
proteininTg-hCBS andexpressingTg-S466Lmiceliversusing nativegelsfollowed byWestern blot analysis.
FIGURE 5. CorrelationbetweenCBS activity,tetramerformation,
and serum tHcy. A: Correlation between CBS tetramer density
and CBS activity (in presence of AdoMet) in the livers of mice of
respective genotype. Black dots represent Tg-hCBS mice and
white dots representTg-S466L mice. B: Correlation between li-
ver CBS activity (in presence of AdoMet) and serum tHcy inTg-
hCBS (n58) andTg-S466L (n59) mice. CBS activity has been
measured in the terms of micromoles (mmol) of cystathionine
formedper milligramof proteinper hr.
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or Serine
One possible explanation for the reduced effectiveness of
p.S466L in lowering tHcy would be that p.S466L might affect the
binding affinity (Km) of the enzyme. To examine this, we
determined the steady state kinetic parameters of p.S466L and
wild-type CBS present in mouse liver extracts. For this analysis, we
specifically chose two mice that had nearly identical CBS protein
levels as judged by Western blot analysis, but had very different
tHcy. As shown in Table 1, both wild-type and p.S466L CBS had
nearly identical Km values for serine, while the p.S466L enzyme
had a slightly lower Km value for homocysteine. These results show
that the p.S466L mutation does not adversely affect substrate
binding, and that this could not be the explanation for the
elevated tHcy observed in p.S466L animals.
DISCUSSION
The experiments in this work were motivated by the apparent
paradox presented by the p.S466L mutation: How can a CBS
enzyme that is enzymatically active in vitro cause homocystinuria
in vivo? In the present study, we found that mice expressing
p.S466L exhibited hyperhomocysteinemia, confirming that this
mutation is disease causing in vivo. The reduced function in vivo
appears to be caused by two processes: 1) the steady state level of
p.S466L protein is generally reduced compared to wild-type
human CBS; and 2) even when the p.S466L protein is present, it
is not as efficient in lowering plasma homocysteine levels in vivo.
As shown in Fig. 1, we observed a high level of variability in the
tHcy of our Tg-S466L animals. Part of the explanation for this
variability is explained by variable CBS expression in the livers of
these mice. Over half of the Tg-S466L mice had no detectable
CBS expression in the liver and the expressing ones generally had
lower CBS levels compared to the control Tg-hCBS mice. The
reduced expression of Tg-S466L protein was not caused by a
reduction in the amount of CBS mRNA produced from the
mutant transgene construct. In fact, the p.S466L mice had 5 to
10-fold more CBS mRNA. These findings show that the reduced
levels of p.S466L protein observed in the mice is due to
posttranscriptional mechanisms. Some possible mechanisms could
include reduced translational efficiency of the message or
increased rates of protein misfolding and subsequent proteolysis.
We think it is unlikely that reduced translational efficiency is the
explanation as the leucine encoded by the mutant TTG codon has
a higher frequency of usage in the human genome than the wild-
type TCG codon [Guigo, 1999]. Therefore, we favor the idea that
in mammalian liver only a small proportion of the p.S466L protein
folds correctly into a native conformation, and that the misfolded
protein is subsequently degraded.
Previous studies have found that recombinant p.S466L
expressed in either E. coli or Chinese hamster fibroblasts is stable
and has enzymatic activity, but that this activity is nonresponsive
to stimulation by AdoMet [Janosik et al., 2001; Maclean et al.,
2002]. In both E. coli and Chinese hamster fibroblasts the Vmax for
the enzyme was estimated to be similar to that of the wild-type
CBS enzyme assayed in the presence of AdoMet, implying that the
enzyme is constitutively activated. We found essentially identical
results in the characterization of p.S466L produced either in S.
cerevisiae or in the livers of Tg-S466L mice. We failed to see
induction of activity by AdoMet and the normalized activity of the
mutant enzyme in vitro was essentially equivalent to the activity
observed in Tg-hCBS mice. We also observed that the p.S466L
enzyme that was present in the liver formed tetramers efficiently,
and that the amount of tetramer present in extracts was an
excellent predictor of in vitro enzyme activity. These findings
confirm that when p.S466L protein is present, it is active and
forms functional tetramers.
Besides affecting the amount of steady-state CBS protein, our
results also suggest that the p.S466L enzyme is less efficient at
lowering serum tHcy. This is shown by the relationship between
liver CBS activity (measured in the presence of AdoMet) and tHcy
in Tg-S466L and Tg-hCBS animals (Fig. 5B). In both Tg-hCBS
and Tg-S466L mice, there was an inverse linear relationship
between CBS activity and tHcy but the slope and intercepts of the
lines were significantly different. One possible explanation for the
difference in behavior would be if the p.S466L mutation affected
substrate binding (Km) such that more enzyme would be required
to metabolize homocysteine. However, our kinetic studies do not
reveal any significant difference in Km that would explain this result
(Table 1). We can think of three possible hypotheses to explain
these findings. First, it may be that there is some as yet unidentified
allosteric effector that stimulates CBS activity in vivo, and that
p.S466L does not respond to this effector. Second, mammalian
CBS is known to bind heme and there is evidence that the enzyme
is 50% less active under strong reducing conditions in vitro [Taoka
et al., 1998]. It is possible that the p.S466L mutation may be much
more severely impaired to the reducing conditions found inside the
cell and that this is not observed in the standard in vitro assay
conditions used in this study. A final possibility is that the p.S466L
mutant form of the enzyme may be sequestered inside the cell in
such a way that it is nonfunctional, but when extracts are prepared
this sequestration is somehow eliminated. One possible candidate
for the sequestering molecules would be molecular chaperone
proteins such as Hsp70, which are known to bind to misfolded
cytoplasmic proteins, and either helps them refold or directs their
degradation via the carboxy terminus of Hsc70 interacting protein
(CHIP) protein [McDonough and Patterson, 2003].
The findings concerning p.S466L suggest that caution must be
used when examining the functional aspects of missense mutations
using recombinant proteins. In general when missense mutations
are identified, their functional effects are tested on recombinant
proteins produced either in E. coli or mammalian cell culture
systems. Our results demonstrate that missense alterations may
have subtle effects on protein stability that vary depending on the
expression system that is used. The ability to test functional effects
TABLE 1. Characterization ofWild-Type and S466L EnzymeFrom Liver
Homocysteine (1AdoMet)
a L-Serine (1AdoMet)
b
Genotype tHcy [mM] Km (mM) Vmax (mmol/mg/hr) Km (mM) Vmax (mmol/mg/hr)
Tg-hCBS 48 2.570.23 0.6370.02 0.7870.10 0.5470.01
Tg-S466L 168 1.170.05 0.6070.01 0.7770.09 0.5670.01
aL-Serinewasused at10mM saturatingconcentration.
bDL-Homocysteinewasused at a saturatingconcentration of 20mM.
HUMAN MUTATION 29(8),1048^1054, 2008 1053of human mutations in the mouse probably represents the closest
approximation to the situation in humans.
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